CRBU on Nasdaq
Caribou Biosciences, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Revolution Medicines (United States), TScan Therapeutics, Inc. or Alpha Cognition Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1329.4%Operating margin3
-1327.4%Net margin3
11.7%Revenue growth, 20253
-121.2%Return on equity3
-$112.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 85% of the revenue Caribou Biosciences, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $9.3M | $9.5M |
| Outside the United States | $724.0K | $1.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development99¢$109.4M
- Income tax1¢$550.0K
Out of $11.2M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $109.4M | $130.2M |
| General and administrative | $37.9M | $46.5M |
| Total operating expenses | $159.5M | $176.6M |
| Loss from operations | -$148.3M | -$166.6M |
| Other income, net | $8.8M | $17.5M |
| Total other (expense) income | -$331.0K | $17.5M |
| Net loss before benefit from income taxes | -$148.7M | -$149.1M |
| Benefit from income taxes | -$550.0K | -$9.0K |
| Net loss | -$148.1M | -$149.1M |
| Net unrealized (loss) gain on available-for-sale marketable securities, net of tax | -$152.0K | $225.0K |
| Net comprehensive loss | -$148.3M | -$148.9M |
| Net loss per share, basic (in dollars per share) | -$1.59 | -$1.65 |
| Net loss per share, diluted (in dollars per share) | -$1.59 | -$1.65 |
| Weighted average common shares outstanding, basic (in shares) | 93.4M shares | 90.3M shares |
| Weighted average common shares outstanding, diluted (in shares) | 93.4M shares | 90.3M shares |
| Licensing and collaboration revenue (including $2,487 and $4,110 for years ended December 31, 2025, and December 31, 2024, respectively, from related parties) | $11.2M | $10.0M |
| Impairment charges | $12.2M | $0 |
| Impairment Of Equity Method Investment | -$9.2M | $0 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $12.4M | $16.3M | |
| Marketable securities, short-term | $127.0M | $193.2M | |
| Accounts receivable | $69.0K | $265.0K | |
| Contract assets | $1.0M | $1.2M | |
| Other receivables | $1.9M | $1.8M | |
| Prepaid expenses and other current assets | $2.9M | $6.6M | |
| Total current assets | $145.2M | $219.4M | |
| Marketable securities, long-term | $3.5M | $39.8M | |
| Property and equipment, net | $6.8M | $19.3M | |
| Operating lease, right of use assets | $17.7M | $20.0M | |
| Other assets | $2.2M | $5.5M | |
| TOTAL ASSETS | $175.4M | $313.3M | |
| Accounts payable | $5.8M | $2.5M | |
| Accrued expenses and other current liabilities | $16.5M | $23.6M | |
| Operating lease liabilities, current | $1.2M | $1.4M | |
| Total current liabilities | $25.4M | $30.7M | |
| Deferred revenue, net of current portion ($0 and $1,243 from related party as of December 31, 2025, and December 31, 2024, respectively) | $1.8M | $3.3M | |
| MSKCC success payments liability | $0 | $785.0K | |
| Operating lease liabilities, non-current | $26.0M | $25.1M | |
| Deferred tax liabilities | $0 | $548.0K | |
| Total liabilities | $53.2M | $60.4M | |
| Common stock, par value $0.0001 per share, 300,000,000 shares authorized at December 31, 2025, and December 31, 2024; 95,143,690 and 92,378,577 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively | $9.0K | $9.0K | |
| Additional paid-in-capital | $718.6M | $701.1M | |
| Accumulated other comprehensive income | $103.0K | $255.0K | |
| Accumulated deficit | -$596.5M | -$448.4M | |
| Total stockholders equity | $122.2M | $253.0M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $175.4M | $313.3M | |
| Deferred revenue, current | $1.9M | $3.1M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 95.1M shares | 92.4M shares | |
| Common stock, shares outstanding (in shares) | 95.1M shares | 92.4M shares | |
| Equity Method Investments | $0 | $9.3M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$148.1M | -$149.1M |
| Depreciation and amortization | $3.6M | $3.9M |
| Gain on disposal of fixed assets | -$25.0K | -$9.0K |
| Impairment charges | $12.2M | $0 |
| Impairment Of Equity Method Investment | $9.2M | $0 |
| Non-cash consideration for licensing and collaboration revenue | -$9.0K | -$1.6M |
| Change in fair value of equity securities | $99.0K | $111.0K |
| Stock-based compensation expense | $12.7M | $16.7M |
| Change in fair value of MSKCC success payments liability | -$785.0K | -$2.2M |
| Acquired in-process research and development | $0 | $1.6M |
| Accretion of discounts on investments in marketable securities, net | -$1.1M | -$4.7M |
| Non-cash lease expense | $1.8M | $2.2M |
| Accounts receivable | $196.0K | -$117.0K |
| Contract assets | $152.0K | $267.0K |
| Other receivables | -$76.0K | $458.0K |
| Prepaid expenses and other current assets | $3.7M | -$433.0K |
| Other assets | $3.4M | -$3.9M |
| Accounts payable | $3.3M | -$354.0K |
| Accrued expenses and other current liabilities | -$6.3M | $2.1M |
| Deferred revenue, current and long-term | -$2.8M | -$2.5M |
| Operating lease liabilities | -$1.3M | -$621.0K |
| Deferred tax liabilities | -$548.0K | -$10.0K |
| Net cash used in operating activities | -$111.0M | -$138.2M |
| Proceeds from maturities of marketable securities | $252.8M | $397.5M |
| Purchases of marketable securities | -$149.2M | -$304.4M |
| Purchases of property and equipment | -$1.4M | -$4.9M |
| Proceeds from sale of property and equipment | $0 | $13.0K |
| Payments to acquire in-process research and development | $0 | -$1.6M |
| Net cash provided by investing activities | $102.2M | $86.6M |
| Proceeds from exercise of stock options | $6.0K | $618.0K |
| Proceeds from issuances of common stock under ESPP | $745.0K | $914.0K |
| Proceeds from issuances of common stock related to ATM, net of offering expenses | $4.1M | $15.2M |
| Net cash provided by financing activities | $4.8M | $16.7M |
| NET DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | -$3.9M | -$34.9M |
| Purchases of property and equipment included in accounts payable and accrued expenses | $60.0K | $754.0K |
| Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | $2.1M | $0 |
Recent filings
- Oct 6, 20268-K
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Jul 27, 2026SCHEDULE 13G
- Jun 18, 20268-K
- Jun 11, 20268-K
- Jun 5, 2026DEFA14A
- May 7, 20268-K
- May 7, 202610-Q
- May 1, 2026DEFR14A
- Apr 24, 2026DEF 14A
- Apr 24, 2026DEFA14A
- Apr 24, 2026ARS
- Apr 10, 2026PRE 14A
- Mar 31, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9